|
AstraZeneca PLC on Tuesday said its lung cancer antibody drug conjugate Enhertu has received priority review from the Food & Drug Administration in the US.
The Cambridge, England-based pharmaceutical company said the conjugate, developed jointly with Tokyo-based Daiichi Sankyo Co Ltd, showed a 54.9% tumour response rate.
The companies focus on tumours with mutations of the growth-promoting protein HER2. ‘If approved, Enhertu has the potential to become a new standard treatment...offering a much-needed option for patients with HER2-mutant metastatic non-small cell lung cancer who currently have no targeted treatment options,’ said Susan Galbraith, executive vice president of AstraZeneca's oncology research & development arm.
AstraZeneca shares were 0.4% lower at 10,494.00 pence each in London on Tuesday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
